A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free
(progression-free survival) and and the length of time until a participant dies (overall
survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin
calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus
either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat
sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf
murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or
metastatic colorectal cancer who have previously received chemotherapy.

Treatment Sites in Georgia